Suppr超能文献

[1990年至2003年西班牙非甾体抗炎药的使用趋势]

[Trends of non-steroidal anti-inflammatory drugs use in Spain, 1990 through 2003].

作者信息

de Abajo F J, del Pozo J García, del Pino A

机构信息

División de Farmacoepidemiología y Farmacovigilancia, Agencia Española de Medicamentos y Productos Sanitarios, Ministerio de Sanidad y Consumo, Madrid, España.

出版信息

Aten Primaria. 2005 Nov;36(8):424-33. doi: 10.1157/13081056.

Abstract

OBJECTIVE

To know the trends of supply, consumption and pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) in Spain from 1990 through 2003, as well as their costs.

DESIGN

Drug utilization study.

SETTING

National Health System, outpatient setting.

MAIN MEASUREMENTS

Information on drug utilization was obtained from the ALHAQUEM database of the Spanish Ministry of Health, which contains the number of packages sold in community pharmacies and charged to the National Health System. Data were expressed in defined daily doses (DDD) per 1000 inhabitants per day (DHD).

RESULTS

NSAIDs consumption in Spain increased from 23.67 DHD in 1990 to 45.82 DHD in 2003 (a 93.6% increase). Ibuprofen was the NSAID which showed the greatest increase (15.33 DHD in 2003). The consumption of coxibs reached a maximum of 7.74 DHD in 2001, but decreased to 3.59 DHD in 2003 once prior-authorization programs were set up. Over the study period the share of NSAIDs use with a low gastrointestinal risk increased from 29% to 59%. Overall costs of NSAIDs increased from 117 million euro in 1990 to 329 million euro in 2003.

CONCLUSIONS

Over the study period the consumption of NSAIDs in Spain has increased twofold while costs increased threefold. The pattern of use has remarkably changed showing an increasing use of NSAIDs with a better gastrointestinal profile. The impact of coxibs marketing has been moderate.

摘要

目的

了解1990年至2003年西班牙非甾体抗炎药(NSAIDs)的供应、消费及使用模式趋势,以及其成本。

设计

药物利用研究。

地点

国家卫生系统,门诊环境。

主要测量指标

药物利用信息来自西班牙卫生部的ALHAQUEM数据库,该数据库包含社区药房售出并计入国家卫生系统的药品包装数量。数据以每千居民每日限定日剂量(DDD)表示(DHD)。

结果

西班牙NSAIDs的消费量从1990年的23.67 DHD增加到2003年的45.82 DHD(增长93.6%)。布洛芬是增长幅度最大的NSAID(2003年为15.33 DHD)。昔布类药物的消费量在2001年达到最高值7.74 DHD,但在2003年设立预先授权程序后降至3.59 DHD。在研究期间,胃肠道风险较低的NSAIDs使用比例从29%增加到59%。NSAIDs的总成本从1990年的1.17亿欧元增加到2003年的3.29亿欧元。

结论

在研究期间,西班牙NSAIDs的消费量增加了两倍,而成本增加了三倍。使用模式发生了显著变化,胃肠道安全性更好的NSAIDs使用量增加。昔布类药物的市场影响较为温和。

相似文献

1
[Trends of non-steroidal anti-inflammatory drugs use in Spain, 1990 through 2003].
Aten Primaria. 2005 Nov;36(8):424-33. doi: 10.1157/13081056.
2
The outpatient utilization of non-steroidal anti-inflammatory drugs in South Bačka District, Serbia.
Int J Clin Pharm. 2011 Apr;33(2):246-51. doi: 10.1007/s11096-011-9487-0. Epub 2011 Feb 25.
3
Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain.
Ther Adv Musculoskelet Dis. 2021 Apr 29;13:1759720X211010599. doi: 10.1177/1759720X211010599. eCollection 2021.
4
[Use of antihypertensive drugs in Spain (1995-2001)].
Rev Esp Cardiol. 2004 Mar;57(3):241-9.
5
[Prescription of cyclooxygenase-2 inhibitors: an intervention strategy in primary care].
Gac Sanit. 2005 May-Jun;19(3):229-34. doi: 10.1157/13075956.
6
[Trends in antibiotic consumption in Spain, 1985-2000].
Med Clin (Barc). 2002 Apr 27;118(15):561-8. doi: 10.1016/s0025-7753(02)72453-6.
7
[Use of specific drugs for Alzheimer's disease].
Neurologia. 2007 Jun;22(5):275-84.
9
[Use of antihypertensive drugs in Spain, 1985-1995].
Med Clin (Barc). 1998 Feb 28;110(7):247-53.
10
Quality of non-steroidal anti-inflammatory drug prescribing in Croatia (Rijeka) and Sweden (Stockholm).
Eur J Clin Pharmacol. 2002 Jun;58(3):209-14. doi: 10.1007/s00228-002-0449-2. Epub 2002 Apr 26.

引用本文的文献

3
[Use of prescription drugs in Spain and Europe].
Aten Primaria. 2012 Jun;44(6):335-47. doi: 10.1016/j.aprim.2011.06.009. Epub 2011 Oct 22.
4
Use of gastrointestinal prophylaxis in NSAID patients: a cross sectional study in community pharmacies.
Int J Clin Pharm. 2011 Apr;33(2):155-64. doi: 10.1007/s11096-011-9490-5. Epub 2011 Mar 12.
5
Pharmacist intervention reduces gastropathy risk in patients using NSAIDs.
Pharm World Sci. 2008 Dec;30(6):947-54. doi: 10.1007/s11096-008-9258-8. Epub 2008 Oct 19.

本文引用的文献

1
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
Lancet. 2004;364(9450):2021-9. doi: 10.1016/S0140-6736(04)17514-4.
4
A coxib a day won't keep the doctor away.
Lancet. 2004;364(9435):639-40. doi: 10.1016/S0140-6736(04)16906-7.
5
[The use of anxiolytic and hypnotic drugs in Spain (1995-2002)].
Rev Esp Salud Publica. 2004 May-Jun;78(3):379-87. doi: 10.1590/s1135-57272004000300007.
6
Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
Circulation. 2004 Jun 22;109(24):3000-6. doi: 10.1161/01.CIR.0000132491.96623.04. Epub 2004 Jun 14.
7
Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents.
Drug Saf. 2004;27(6):411-20. doi: 10.2165/00002018-200427060-00005.
8
Efficacy and safety of COX 2 inhibitors.
BMJ. 2002 Sep 21;325(7365):607-8. doi: 10.1136/bmj.325.7365.607.
10
Quality of non-steroidal anti-inflammatory drug prescribing in Croatia (Rijeka) and Sweden (Stockholm).
Eur J Clin Pharmacol. 2002 Jun;58(3):209-14. doi: 10.1007/s00228-002-0449-2. Epub 2002 Apr 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验